WO2001020327A1 - Spa in a screening method for modulators of glucokinase - Google Patents
Spa in a screening method for modulators of glucokinase Download PDFInfo
- Publication number
- WO2001020327A1 WO2001020327A1 PCT/GB2000/003495 GB0003495W WO0120327A1 WO 2001020327 A1 WO2001020327 A1 WO 2001020327A1 GB 0003495 W GB0003495 W GB 0003495W WO 0120327 A1 WO0120327 A1 WO 0120327A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glk
- glkrp
- assay
- binding
- compounds
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- the present invention relates to assay methods suitable for identifying compounds which stimulate glucokinase in pancreatic ⁇ -cells, leading to a decreased threshold for insulin secretion.
- the compounds are expected to lower blood glucose by increasing hepatic glucose uptake.
- Such compounds may have utility in the treatment of non-insulin dependent diabetes (NIDDM).
- NIDDM non-insulin dependent diabetes
- the main plasma membrane glucose transporter is GLUT2.
- GLUT2 is not rate limiting with the effect that in these cells the rate of glucose uptake is limited by the rate of phosphorylation of glucose to glucose-6-phosphate (G-6-P), catalysed by glucokinase (GLK) ( Pilkis and Granner 1992, Malaisse 1993).
- GLK has a high (6-10mM) Km for glucose, is not inhibited by physiological concentrations of G-6-P and is predominantly expressed in liver, kidney and pancreatic ⁇ -cells (Pilkis et al 1994 and Caro et al 1995).
- GLK may have an important role in the development of NIDDMs (Glasser et al 1998). Firstly, GLK mutations are believed to be the primary defect responsible for several forms of maturity onset diabetes of youth (MODY) a rare form of NIDDM (Froguel et al 1993, Bell et al 1996 and Shiota et al 1998). Secondly, the constitutive expression of yeast hexokinase gene in transgenic mice has been shown to cause increased insulin secretion and hypoglycaemia. This data offers new evidence in support of a critical role for GLK in determining glucose phosphorylation and insulin secretion rate in the beta cell.
- GLK is associated with a regulatory protein (GLKRP) which binds to and inactivates GLK in the presence of fructose-6-phosphate (F-6-P).
- F-6-P fructose-6-phosphate
- F-l-P Fructose- 1 -phosphate
- inorganic phosphate interfere with the binding of F-6-P thereby preventing binding of
- GLKRP GLKRP to GLK.
- a compound which similarly interferes with the interaction between GLK and GLKRP will effectively stimulate GLK and may offer an opportunity for the development of a novel therapeutic agent for the treatment of NIDDM (Veiga-da-Cunhe etal 1996).
- NIDDM Vandeiga-da-Cunhe etal 1996.
- GLK acts as the rate limiting step in glucose uptake and utilisation.
- a compound which stimulates GLK by interfering with the interaction between GLK and GLKRP will lower blood glucose by increasing hepatic glucose uptake.
- increased glucose metabolism leads through increased ⁇ cell [ATP]/[ADP] concentration ratio, to closure of the ATP-dependant K + channels, hence to membrane depolarisation and opening of voltage gated Ca + channels.
- the ensuing increase in ⁇ cell Ca 2+ provokes a glucose sensitive insulin release ( Matschinsky et al 1993).
- a compound which stimulates GLK by interfering with the interaction between GLK and GLKRP in ⁇ cells will thus also lead to a decreased glucose threshold for insulin secretion. Both effects will be of benefit in the treatment of NIDDM.
- Enzymatic activity of GLK may be measured by incubating GLK, ATP and glucose as shown in Figure 2.
- the rate of product formation may be determined by coupling the assay to a G-6-P dehydrogenase, NADP/NADPH system and measuring the increase in optical density at 340nm ( Matschinsky et al 1993).
- this type of assay procedure has a number of disadvantages.
- use of such an assay method to screen compounds would identify all compounds which modulate enzyme activity, regardless of their mechanism of action.
- the assay would detect compounds which directly activate glucokinase in the absence of the GLKRP, compounds which prevent F-6-P binding or which act as F-l-P mimetics.
- the spectrophotometric assay would equally well detect compounds which inhibited a protein to protein interaction between GLK and GLKRP.
- assay methods which are able to provide information on the precise mechanism of action of compounds which modulate GLK activity.
- assay methods are needed to identify compounds which stimulate GLK activity by preventing the binding interaction between GLK and GLKRP.
- Such assay methods are provided by the GLK/GLKRP binding assay and the F-6-P/GLKRP binding assay disclosed in the present invention.
- new methods for identifying compounds which modulate GLK In particular, we have developed an assay system which identifies compounds which modulate GLK by preventing the interaction between GLK and GLKRP. It is to be understood that whenever an assay system as described herein is referred to, a method and/or process utilising said assay system is also contemplated.
- the assay system comprises two related assay methods; a GLK/GLKRP binding assay and a F-6-P / GLKRP binding assay.
- the GLK/GLKRP binding assay provides an assay method for measuring the binding interactions between GLK and GLKRP. The method may be used to identify compounds which modulate GLK by modulating the interaction between GLK and GLKRP.
- GLKRP and GLK are incubated with an inhibitory concentration of F-6-P, optionally in the presence of test compound, and the extent of interaction between GLK and GLKRP is measured.
- the F-6-P / GLKRP binding assay provides an assay method for measuring the binding interaction between GLKRP and F-6-P. This method may be used to provide further information on the mechanism of action of the compounds.
- Compounds identified in the GLK/GLKRP binding assay may modulate the interaction of GLK and GLKRP either by displacing F-6-P or by modifying the GLK/GLKRP interaction in some other way.
- protein-protein interactions are generally known to occur by interactions through multiple binding sites. It is thus possible that a compound which modifies the interaction between GLK and GLKRP could act by binding to one or more of several different binding sites.
- the F-6-P / GLKRP binding assay identifies only those compounds which modulate the interaction of GLK and GLKRP by displacing F-6-P from its binding site on GLKRP.
- GLKRP is incubated with test compound and an inhibitory concentration of F-6-P, in the absence of GLK, and the extent of interaction between F-6-P and GLKRP is measured.
- an assay method which method comprises measurement of the binding interaction between GLKRP and either GLK or F-6-P.
- the assay method comprises: (i) contacting
- a particularly preferred embodiment of the assay methods of the invention is a scintillation proximity assay (SPA).
- SPA scintillation proximity assay
- SPA involves the use of fluomicrospheres coated with acceptor molecules such as enzymes or receptors, to which a ligand will bind selectively in a reversible manner (Bosworth and Towers, 1989).
- acceptor molecules such as enzymes or receptors
- the technique requires the use of a ligand labelled with an isotope that emits low energy radiation which is dissipated easily into an aqueous medium.
- bound labelled ligands will be in close proximity to the fluomicrospheres, allowing the emitted energy to activate the fluor and produce light.
- the vast majority of unbound labelled ligands will be too far from the fluomicrospheres to enable the transfer of energy. Bound ligands produce light but free ligands do not, allowing the extent of ligand binding to be measured without the need to separate bound and free ligand.
- a scintillation proximity assay may be used in either or both the GLK/GLKRP binding assay and the F-6-P/GLKRP binding assay.
- a scintillation proximity assay for measuring the interaction between GLK and GLKRP, wherein one of (a), (b) or (c) as defined in Assay Method 1 is radiolabelled and another of (a), (b) or (c) as defined in Assay Method 1 is bound to a fluomicrosphere.
- the radiolabelled ligand is [ 3 H]F-6-P.
- GLK is biotinylated and the fluomicrospheres are coated with streptavidin. Biotinylated GLK binds to the streptavidin coated fluomicrospheres as shown in Figure 3.
- GLK, GLKRP and [ 3 H]F-6-P may be detected by the emission of light from the fluomicrospheres.
- Compounds which modulate the interaction between GLK and GLKRP may be identified by a change in light emission from the fluomicrospheres.
- the radiolabelled ligand is [ 3 H]F-6-P.
- (a) as defined in Assay Method 1 is labelled with a FLAG tag, and the fluomicrospheres are coated with an anti-FLAG antibody.
- (a) as defined in Assay Method 1 is biotinylated, and the fluomicrospheres are coated with streptavidin.
- Binding of F-6-P to GLKRP may be detected by the emission of light from the fluomicrospheres.
- Compounds which displace F-6-P from its binding site on GLKRP may be identified by a change in light emission from the fluomicrospheres.
- Compounds which may be tested in the assays include simple organic molecules, commonly known as "small molecules", for example those having a molecular weight of less than 2000 Daltons.
- the assay may also be used to screen compound libraries such as peptide libraries, including synthetic peptide libraries and peptide phage libraries.
- Other suitable molecules include antibodies, nucleotide sequences and any other molecules which stimulate GLK.
- Modulation of activity comprises either activation or inhibition.
- a compound which modulates GLK is a compound which either stimulates or inhibits GLK.
- modulator of GLK and “GLK modulator” are also used herein to refer to a compound that either stimulates or inhibits GLK.
- the compounds of the invention have utility in the treatment of NTDDMs, in general this would arise by stimulation of GLK.
- An inhibiting concentration of F-6-P is one which reduces the rate of the GLK enzyme reaction. Preferably the rate should be reduced by greater than 85%. This reduction would typically be achieved using a concentration of F-6-P of 25 ⁇ M (when used with rat GLKRP ) and lO ⁇ M (when used with human GLKRP).
- step (i) of Assay Method 1 is carried out in the presence of glucose. Any convenient concentration of glucose may be used for example 1, 2, 5, 10, 50 or 100 mM. In a particularly preferred embodiment the concentration of glucose is 5 mM.
- a particular advantage of the assays of the invention is that they are very convenient to use.
- the assays can be carried out in 96-well microplates allowing large numbers of compounds to be tested simultaneously.
- GLK and GLKRP used in the assays of the invention are human proteins.
- homologue we mean a protein with a similar amino acid sequence to a GLK protein sequence or a GLKRP protein sequence as set out in Tanizawa et al 1991 and Bonthron, D.T. et al 1994 respectively.
- the homologue may be a protein from the same species, i.e. a homologous protein family member.
- the homologue may be a similar protein from a different species such as rat or mouse, useful in providing animal models of NTDDMs.
- Convenient homologues include those which share a sequence similarity of 70% or greater with a GLK or GLKRP sequence set out in Tanizawa et al 1991 and Bonthron, D.T. et al 1994 respectively.
- Preferred sequence similarities include 75% and 80% identity, other preferred sequence similarities include 85% and 90% identity, further preferred sequence similarities include 95% identity.
- Fragments as used herein include peptides containing six or more consecutive amino acids of the GLK and GLKRP sequences set out in (Tanizawa et al 1991 and Bonthron, D.T. et al 1994) respectively.
- the fragments possess the same or essentially the same biological activity as the full length molecules from which they are derived.
- the fragments may represent for example more than 1% or more than 5% or more than 10% or more than 50% or more than 90% of the full length molecules from which they are derived.
- composition which comprises a novel modulator of GLK, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.
- the composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example a cream, ointment, gel or aqueous or oily solution or suspension; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or suspension.
- the above compositions may be prepared in a conventional manner using conventional excipients.
- the invention also includes a method of treating NIDDM or a medical condition mediated alone or in part by GLK which comprises administering to a warm-blooded animal requiring such treatment an effective amount of a GLK modulator as defined above.
- the invention also provides the use of a GLK modulator in the production of a medicament for use in the treatment of NTDDM.
- the size of the dose of a GLK modulator, for therapeutic or prophylactic purposes will naturally vary according to the nature and severity of the NIDDM, the age and sex of the patient and the route of administration, according to well-known principles of medicine.
- a novel GLK modulator for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range for example 0.5mg to 75mg per kg body weight is received, given if required in individual doses. In general lower doses will be administered when a parenteral route is employed.
- a dose in the range for example 0.5mg to 30mg per kg body weight will generally be used.
- a dose in the range for example 0.5mg to 25mg per kg body weight will be used.
- Figure 1 shows the uptake of glucose into a cell by the plasma membrane glucose transporter GLUT2, and its conversion to glucose-6-phosphate (G-6-P) by glucokinase
- GLK glucokinase regulatory protein
- F-6-P fructose-6- phosphate
- Fructose-6-phosphate is displaced from its binding site on GLKRP by fructose- 1- phosphate (F-l-P), leading to dissociation of GLK and GLKRP and resulting in increased glucokinase activity and stimulation of glucose metabolism.
- Figure 2 shows a reaction pathway in which glucose is phosphorylated to G-6-P by glucokinase in the presence of ATP.
- the rate of the reaction may be determined by measuring the reduction of NADP to NADPH, detected as a change in optical density at 340nm.
- FIG. 3 shows a preferred embodiment of a GLK/GLKRP binding assay.
- the diagram illustrates the emission of light from streptavidin coated fluomicrospheres on formation of a binding complex between biotinylated GLK, GLKRP and [ 3 H]F-6-P.
- Figure 4 shows a preferred embodiment of a GLK/GLKRP binding assay. The diagram illustrates the emission of light from streptavidin coated fluomicrospheres on formation of a binding complex between biotinylated GLK, GLKRP and [ 3 H]F-6-P.
- Figure 4 shows a preferred embodiment of a GLK/GLKRP binding assay. The diagram illustrates the emission of light from streptavidin coated fluomicrospheres on formation of a binding complex between biotinylated GLK, GLKRP and [ 3 H]F-6-P.
- Figure 4 shows a preferred embodiment of a GLK/GLKRP binding assay. The diagram illustrates the emission of light from streptavidin coated fluomicrosphere
- Figure 4 shows a preferred embodiment of a F-6-P / GLKRP binding assay.
- the diagram illustrates the emission of light from fluomicrospheres coated with protein A and an anti-FLAG antibody, on formation of a binding complex between FLAG-tagged GLKRP and [ ⁇ ]F-6-P.
- Figure 5 is a titration curve showing the displacement of F-l-P by F-6-P, obtained using the GLK/GLKRP scintillation proximity assay of the invention.
- Human liver total mRNA was prepared by polytron homogenisation in 4M guanidine isothiocyanate, 2.5mM citrate, 0.5% Sarkosyl, lOOmM ⁇ -mercaptoethanol, followed by centrifugation through 5.7M CsCl, 25mM sodium acetate at 135,OOOg (max) as described in Sambrook J, Fritsch EF & Maniatis T, 1989.
- Poly A + mRNA was prepared directly using a FastTrackTM mRNA isolation kit (Invitrogen).
- GLK and GLKRP cDNA sequences Human GLK and GLKRP cDNA was obtained by PCR from human hepatic mRNA using established techniques described in Sambrook, Fritsch & Maniatis, 1989. PCR primers were designed according to the GLK and GLKRP cDNA sequences shown in Tanizawa et al 1991 and Bonthron, D.T. et al 1994.
- GLK and GLKRP cDNA was cloned in E. coli using pBluescript II, (Short et al 1998) a recombinant cloning vector system similar to that employed by Yanisch-Perron C et al (1985), comprising a colEI-based replicon bearing a polylinker DNA fragment containing multiple unique restriction sites, flanked by bacteriophage T3 and T7 promoter sequences; a filamentous phage origin of replication and an ampicillin drug resistance marker gene.
- E coli transformations were generally carried out by electroporation. 400 ml cultures of strains DH5 ⁇ or BL21(DE3) were grown in L-broth to an OD 600 of 0.5 and harvested by centrifugation at 2,000g. The cells were washed twice in ice-cold deionised water, resuspended in 1ml 10% glycerol and stored in aliquots at -70°C. Ligation mixes were desalted using Millipore V seriesTM membranes (0.0025mm) pore size).
- GLK was expressed from the vector pTB375NBSE in E.coli BL21 cells, producing a recombinant protein containing a 6-His tag immediately adjacent to the N-terminal methionine.
- another suitable vector is pET21(+)DNA, Novagen, Cat number 697703. The 6-His tag was used to allow purification of the recombinant protein on a column packed with nickel-nitrilotriacetic acid agarose purchased from Qiagen (cat no 30250).
- GLKRP was expressed from the vector pFLAG CTC (IBI Kodak) in E.coli BL21 cells, producing a recombinant protein containing a C-terminal FLAG tag.
- the protein was purified initially by DEAE Sepharose ion exchange followed by utilisation of the FLAG tag for final purification on an M2 anti-FLAG immunoaffinity column purchased from Sigma- Aldrich (cat no. A1205).
- Biotinylation of GLK GLK was biotinylated by reaction with biotinamidocaproate N-hydroxysuccinimide ester (biotin-NHS) purchased from Sigma-Aldrich (cat no. B2643). Briefly, free amino groups of the target protein (GLK) are reacted with biotin-NHS at a defined molar ratio forming stable amide bonds resulting in a product containing covalently bound biotin. Excess, non-conjugated biotin-NHS is removed from the product by dialysis. Specifically, 7.5mg of GLK was added to 0.3 lmg of biotin-NHS in 4mL of 25mM HEPES pH7.3, 0.15M KCl,
- Recombinant human GLK and GLKRP were used to develop a "mix and measure" 96 well SPA (scintillation proximity assay).
- a schematic representation of the assay is given in Figure 3).
- GLK (Biotinylated) and GLKRP are incubated with streptavidin linked SPA beads (Amersham) in the presence of an inhibitory concentration of radiolabelled [3H]F-6-P (Amersham Custom Synthesis TRQ8689), giving a signal as depicted in Figure 3.
- Compounds which either displace the F-6-P or in some other way disrupt the GLK / GLKRP binding interaction will cause this signal to be lost. Binding assays were performed at room temperature for 2 hours.
- the reaction mixtures contained 50mM Tris-HCl (pH 7.5), 2mM ATP, 5mM MgCl 2 , 0.5mM DTT, recombinant biotinylated GLK ( 0.1 ⁇ g), recombinant GLKRP (0.1 ⁇ g), 0.05mCi [3H] F-6-P (Amersham) to give a final volume of lOO ⁇ l.
- the extent of GLK/GLKRP complex formation was determined by addition of O.lmg/well avidin linked SPA beads (Amersham) and scintillation counting on a Packard TopCount NXT.
- Recombinant human GLKRP was used to develop a "mix and measure" 96 well scintillation proximity assay.
- a schematic representation of the assay is given in Figure 4).
- FLAG-tagged GLKRP is incubated with protein A coated SPA beads (Amersham) and an anti-FLAG antibody in the presence of an inhibitory concentration of radiolabelled [3FTJF-6- P.
- a signal is generated as depicted in Figure 4. Compounds which displace the F-6-P will cause this signal to be lost.
- a combination of this assay and the GLK/GLKRP binding assay will allow the observer to identify compounds which disrupt the GLK/GLKRP binding interaction by displacing F-6-P.
- Binding assays were performed at room temperature for 2 hours.
- the reaction mixtures contained 50mM Tris-HCl (pH 7.5), 2mM ATP, 5mM MgCl 2 , 0.5mM DTT, recombinant FLAG tagged GLKRP (0.1 ⁇ g), Anti-Flag M2 Antibody (0.2 ⁇ g) ( IBI Kodak), 0.05mCi [3H] F-6-P (Amersham) to give a final volume of lOO ⁇ l.
- the extent of F-6-P/GLKRP complex formation was determined by addition of O.lmg/well protein A linked SPA beads (Amersham) and scintillation counting on a Packard TopCount
- GLKRP protein antibodies or fragments thereof can be used to decrease the inappropriately enhanced inhibition of GLK by GLKRP which occurs in certain pathological conditions including diabetes.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU70290/00A AU7029000A (en) | 1999-09-15 | 2000-09-13 | Spa in a screening method for modulators of glucokinase |
EP00958878A EP1218742A1 (en) | 1999-09-15 | 2000-09-13 | Spa in a screening method for modulators of glucokinase |
JP2001523862A JP2003509070A (en) | 1999-09-15 | 2000-09-13 | Assay |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9921684.8 | 1999-09-15 | ||
GBGB9921684.8A GB9921684D0 (en) | 1999-09-15 | 1999-09-15 | Assays |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001020327A1 true WO2001020327A1 (en) | 2001-03-22 |
Family
ID=10860872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/003495 WO2001020327A1 (en) | 1999-09-15 | 2000-09-13 | Spa in a screening method for modulators of glucokinase |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1218742A1 (en) |
JP (1) | JP2003509070A (en) |
AU (1) | AU7029000A (en) |
GB (1) | GB9921684D0 (en) |
WO (1) | WO2001020327A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006066599A2 (en) * | 2004-12-22 | 2006-06-29 | Rheoscience A/S | Mas related g protein coupled receptors as drug targets |
US7199140B2 (en) | 2001-06-26 | 2007-04-03 | Astrazeneca Ab | Vinyl phenyl derivatives as GLK activators |
WO2007039177A2 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
US7230108B2 (en) | 2002-11-19 | 2007-06-12 | Astrazeneca Ab | Quinoline derivatives as glucokinase ligands |
US7390908B2 (en) | 2001-08-17 | 2008-06-24 | Astrazeneca Ab | Compounds effecting glucokinase |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021330A1 (en) * | 1992-04-22 | 1993-10-28 | Zymogenetics, Inc. | Human glutamine:fructose-6-phosphate amino-transferase |
WO1998020024A1 (en) * | 1996-11-04 | 1998-05-14 | Merck Frosst Canada & Co. | Ligands for phosphatase binding assay |
-
1999
- 1999-09-15 GB GBGB9921684.8A patent/GB9921684D0/en not_active Ceased
-
2000
- 2000-09-13 EP EP00958878A patent/EP1218742A1/en not_active Withdrawn
- 2000-09-13 AU AU70290/00A patent/AU7029000A/en not_active Abandoned
- 2000-09-13 WO PCT/GB2000/003495 patent/WO2001020327A1/en not_active Application Discontinuation
- 2000-09-13 JP JP2001523862A patent/JP2003509070A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021330A1 (en) * | 1992-04-22 | 1993-10-28 | Zymogenetics, Inc. | Human glutamine:fructose-6-phosphate amino-transferase |
WO1998020024A1 (en) * | 1996-11-04 | 1998-05-14 | Merck Frosst Canada & Co. | Ligands for phosphatase binding assay |
Non-Patent Citations (4)
Title |
---|
DETHEUX M ET AL: "EFFECTORS OF THE REGULATORY PROTEIN ACTING ON LIVER GLUCOKINASE A KINETIC INVESTIGATION", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 200, no. 2, 1991, pages 553 - 562, XP000980285, ISSN: 0014-2956 * |
VAN SCHAFTINGEN EMILE ET AL: "Short-term control of glucokinase activity: Role of a regulatory protein.", FASEB JOURNAL, vol. 8, no. 6, 1994, pages 414 - 419, XP002158048, ISSN: 0892-6638 * |
VAN SCHAFTINGEN, E ETAL.: "A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose-6-phosphate and fructose-1-phosphate", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 179, no. 1, 15 January 1989 (1989-01-15), pages 179 - 184, XP000980294 * |
VANDERCAMMEN A ET AL: "THE MECHANISM BY WHICH RAT LIVER GLUCOKINASE IS INHIBITED BY THE REGULATORY PROTEIN", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 191, no. 2, 1990, pages 483 - 490, XP000980287, ISSN: 0014-2956 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7199140B2 (en) | 2001-06-26 | 2007-04-03 | Astrazeneca Ab | Vinyl phenyl derivatives as GLK activators |
US7390908B2 (en) | 2001-08-17 | 2008-06-24 | Astrazeneca Ab | Compounds effecting glucokinase |
EP1987831A1 (en) | 2001-08-17 | 2008-11-05 | AstraZeneca AB | Compounds effecting glucokinase |
US7230108B2 (en) | 2002-11-19 | 2007-06-12 | Astrazeneca Ab | Quinoline derivatives as glucokinase ligands |
WO2006066599A2 (en) * | 2004-12-22 | 2006-06-29 | Rheoscience A/S | Mas related g protein coupled receptors as drug targets |
WO2006066599A3 (en) * | 2004-12-22 | 2006-08-17 | Rheoscience As | Mas related g protein coupled receptors as drug targets |
WO2007039177A2 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
Also Published As
Publication number | Publication date |
---|---|
JP2003509070A (en) | 2003-03-11 |
GB9921684D0 (en) | 1999-11-17 |
EP1218742A1 (en) | 2002-07-03 |
AU7029000A (en) | 2001-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Christian et al. | Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes | |
JP4638549B2 (en) | Protein interacting with IGF-1 receptor, gene encoding the same and use thereof | |
Fiordaliso et al. | Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death | |
US20030105057A1 (en) | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment | |
Hook et al. | TBC1D1 interacting proteins, VPS13A and VPS13C, regulate GLUT4 homeostasis in C2C12 myotubes | |
AU748953B2 (en) | Ligands for discoidin domain receptor tyrosine kinases and complexes thereof | |
US6159704A (en) | Phosphatase modulator | |
EP1218742A1 (en) | Spa in a screening method for modulators of glucokinase | |
US20040028684A1 (en) | Cancer diagnosis and assays for screening anti-cancer agents | |
US7364870B2 (en) | MK2 interacting proteins | |
JP2007515162A (en) | Screening method using CTGF and TRKA receptors for the identification of compounds used in the treatment of fibrosis | |
WO1998041090A1 (en) | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment | |
US20060094013A1 (en) | Salt-inducible kinases 2 and use thereof | |
US7097996B2 (en) | Methods of screening test compounds using GADD34L, an eIF2α-specific phosphatase subunit | |
EP1658504B1 (en) | Inhibition of s6 kinase activity for the treatment of insulin resistance | |
US20050026233A1 (en) | Methods of monitoring and modulating LKB1 activity and its downstream targets | |
EP1556505B1 (en) | Modulation of s6 kinase activity for the treatment of obestiy | |
Fu et al. | Design of negative‐regulating proteins of Rheb/mTORC1 with much‐reduced sizes of the tuberous sclerosis protein complex | |
WO2002022862A2 (en) | Methods for identifying modulators of protein interactions | |
US20050118644A1 (en) | Interaction of NMDA receptor with protein tyrosine phosphatase | |
US20160291017A1 (en) | Biomarker for melk activity and methods of using same | |
CA2928464A1 (en) | Biomarker for melk activity and methods of using same | |
Strachan | P90 Ribosomal S6 Kinase 2 (RSK2) Directly Phosphorylates the 5-HT2A Serotonin Receptor thereby Modulating Signaling | |
US20050266509A1 (en) | Interaction of NMDA receptor with protein tyrosine phosphatase | |
US20040072275A1 (en) | Interaction of NMDA receptor with protein tyrosine phosphatase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 523862 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000958878 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000958878 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000958878 Country of ref document: EP |